International Journal of Hematology

DOI: 10.1007/s12185-019-02679-x Pages: 306-312

Post-treatment improvement of NK cell numbers predicts better survival in myeloma patients treated with thalidomide-based regimens

1. UMAE Especialidades Centro Médico Nacional La Raza, Instituto Mexicano del Seguro Social, Hematology Department

2. Unidad de Investigación de Medicina Traslacional en Enfermedades Hemato-Oncologicas, UMAE Especialidades Centro Médico Nacional La Raza, Instituto Mexicano del Seguro Social

3. Unidad de Investigación Medica en Trombosis, Hemostasia y Aterogenesis Hospital Carlos Mc Gregor, Instituto Mexicano del Seguro Social

4. Escuela Nacional de Ciencias Biologicas, Instituto Politecnico Nacional

Correspondence to:
Jorge Vela-Ojeda
Email: velaj12x@prodigy.net.mx

Close

Abstract

Multiple myeloma (MM) is a disease characterized by antitumoral immune dysfunction. The objective of the present study was to determine lymphocyte subsets (B, T, NK, NKT, iNKT, dendritic cells, and regulatory T cells) in 68 newly diagnosed patients and 113 healthy donors. Lymphocyte subsets were studied in the same patients 6 months after treatment. Pre-treatment values of CD4+ T cells, NK cells, type 2 dendritic cells, and B cells in MM patients were lower than in healthy donors. Forty patients (59%) received MPT treatment and 28 (41%) thal–dex. Patients with no response to treatment, exhibited a decrease in CD4+ T cells and NK cells, as well as an increase in Treg cell numbers. Median DFS and OS was lower in patients not achieving response, in patients having low numbers of NK cells, and higher values of LDH. The number of CD4 T cells, NK, DC2, and B cells at diagnosis is lower in patients with MM. Non-responder patients had lower CD4 and NK, but higher Treg cell values. Patients in which response is not achieved, and those holding lower values of NK cells and higher levels of LDH, have poor DFS and OS.

To access the full text, please Sign in

If you have institutional access, please click here

Share the Knowledge